Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

MLA

Negida, Ahmed, et al. “Efficacy of the Iron-Chelating Agent, Deferiprone, in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis.” CNS Neuroscience & Therapeutics, vol. 30, no. 2, Feb. 2024, p. e14607. EBSCOhost, https://doi.org/10.1111/cns.14607.

APA

Negida, A., Hassan, N. M., Aboeldahab, H., Zain, Y. E., Negida, Y., Cadri, S., Cadri, N., Cloud, L. J., Barrett, M. J., & Berman, B. (2024). Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson’s disease: A systematic review and meta-analysis. CNS Neuroscience & Therapeutics, 30(2), e14607. https://doi.org/10.1111/cns.14607

Chicago

Negida, Ahmed, Nafisa M Hassan, Heba Aboeldahab, Youmna E Zain, Yasmin Negida, Shirin Cadri, Nivin Cadri, Leslie J Cloud, Matthew J Barrett, and Brian Berman. 2024. “Efficacy of the Iron-Chelating Agent, Deferiprone, in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis.” CNS Neuroscience & Therapeutics 30 (2): e14607. doi:10.1111/cns.14607.